טוען...
Early Adoption of Dupilumab in the Medicare Population in 2017
Background: In March of 2017, dupilumab became the first FDA approved injectable biologic for treatment of moderate-to-severe atopic dermatitis (AD). As the first drug in this class for AD, dupilumab has revolutionized the disease’s treatment and improved patient outcomes significantly. Previous wor...
שמור ב:
| הוצא לאור ב: | Yale J Biol Med |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
YJBM
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7757055/ https://ncbi.nlm.nih.gov/pubmed/33380928 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|